Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 7, 2011, Pages 906-911

  Pettit, April C ^a   Kaltenbach, L A ^b   Maruri, F ^a   Cummins, J ^c   Smith, T R ^c   Warkentin, J V ^c   Griffin, M R ^a   Sterling, T R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TENNESSEE DEPARTMENT OF HEALTH   (United States)

Author keywords

Human immunodeficiency virus infection; Re infection; Recurrence; Relapse; Tuberculosis

Indexed keywords

ADULT; ARTICLE; BACTERIUM ISOLATE; CASE CONTROL STUDY; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ADULT; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HIV INFECTIONS; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; RISK FACTORS; TENNESSEE; TIME FACTORS; TUBERCULOSIS;

EID: 79958703806     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0448     Document Type: Article

References (38)

1. Chiang C Y, Riley L W. Exogenous reinfection in tuberculosis. Lancet Infect Dis 2005; 5: 629-636.
2. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
3. Johnson J, Kagal A, Bharadwaj R. Factors associated with drug resistance in pulmonary tuberculosis. Indian J Chest Dis Allied Sci 2003; 45: 105-109.
4. Garcia-Garcia M L, Ponce de L A, Jimenez-Corona M E, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 2000; 160: 630-636. (Pubitemid 30140412)
5. Fujiwara P I, Cook S V, Rutherford C M, et al. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med 1997; 157: 531-536.
6. Driver C R, Munsiff S S, Li J, Kundamal N, Osahan S S. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001; 33: 1762-1769. (Pubitemid 33044545)
7. Nettles R E, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38: 731-736. (Pubitemid 38333871)
8. Nahid P, Gonzalez L C, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175: 1199-1206. (Pubitemid 46855463)
9. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1987; 136: 1339-1342.
10. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991; 143 (4 Pt 1): 700-706.
11. Combs D L, O'Brien R J, Geiter L J. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112: 397-406. (Pubitemid 20098520)
12. Chang K C, Leung C C, Yew W W, Chan S L, Tam C M. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 1153-1158. (Pubitemid 44772087)
13. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian Working Group/British Medical Research Council cooperative study. Am Rev Respir Dis 1984; 129: 921-928.
14. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1975; 1: 119-124.
15. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1: 1079-1085.
16. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184. (Pubitemid 24121986)
17. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528-534.
18. Jick S S, Lieberman E S, Rahman M U, Choi H K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55: 19-26. (Pubitemid 43235123)
19. Inghammar M, Ekbom A, Engstrom G, et al. COPD and the risk of tuberculosis - a population-based cohort study. PLoS One 2010; 5: e10138.
20. Benfield T, Lange P, Vestbo J. COPD stage and risk of hospitalization for infectious disease. Chest 2008; 134: 46-53. (Pubitemid 352008762)
21. Lienhardt C, Fielding K, Sillah J S, et al. Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa. Int J Epidemiol 2005; 34: 914-923. (Pubitemid 41418843)
22. Corbett E L, Churchyard G J, Clayton T C, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000; 14: 2759-2768. (Pubitemid 32118730)
23. Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693. (Pubitemid 33124328)
24. Crampin A C, Mwaungulu J N, Mwaungulu F D, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010; 24: 417-426.
25. Narayanan S, Swaminathan S, Supply P, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis 2010; 201: 691-703.
26. Jasmer R M, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004; 170: 1360-1366. (Pubitemid 39657201)
27. American Thoracic Society. Treatment of tuberculosis. Morb Mortal Wkly Rep 2003; 52 [RR-11]: 735-739.
28. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. Geneva, Switzerland: WHO, 2009.
29. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 1997; 46 (RR-10): 1-55.
30. Bergstralh E K J. Locally written SAS macros. Rochester, MN, USA: Mayo Clinic Division of Biomedical Statistics and Informatics, 2003. http://mayoresearch.mayo.edu/mayo/research/biostat/sasmacros.cfm Accessed April 2011.
31. Van Embden J D, Cave M D, Crawford J T, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-409. (Pubitemid 23028649)
32. Mazars E, Lesjean S, Banuls A L, et al. High-resolution mini-satellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. Proc Natl Acad Sci U S A 2001; 98: 1901-1906. (Pubitemid 32165595)
33. van Buuren S, Boshuizen H C, Knook D L. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 681-694. (Pubitemid 29126744)
34. Arbogast P G, Ray W A. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 2009; 18: 67-80.
35. Arbogast P G, Kaltenbach L, Ding H, Ray W A. Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology 2008; 19: 30-37. (Pubitemid 350295136)
36. Holt E. Epidemiologic profile of tuberculosis in Tennessee, 2005. Nashville, TN, USA: Tennessee Department of Health, Tuberculosis Elimination Program, 2006.
37. Khan F A, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-1299.
38. Nunn A J, Phillips P P, Mitchison D A. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010; 14: 241-242.